2012 and beyond: Potential for the start of a second pre-antibiotic era?

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 9, 2012, Pages 2062-2068

  Appelbaum, Peter C ^a  

^a NONE   (United States)

Author keywords

Approval problems; Bacterial resistance; Financial considerations; Lack of expertise; Lack of interest; Misinformation; Public apathy

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AVIBACTAM; AZITHROMYCIN; BAL 30072; CAZ 104; CEFIXIME; CEFTAROLINE; CEFTOBIPROLE; COLISTIN; COTRIMOXAZOLE; CXA 201; DALBAVANCIN; DAPTOMYCIN; DELAFLOXACIN; FIDAXOMICIN; FUSIDIC ACID; GSK 2251052; MINOCYCLINE; OMADACYCLINE; ORITAVANCIN; PIPERACILLIN PLUS TAZOBACTAM; PLAZOMICIN; PNEUMOCOCCUS VACCINE; POLYMYXIN B; SOLITHROMYCIN; TELAVANCIN; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; WCK 771;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; COMMUNITY ACQUIRED PNEUMONIA; DRUG APPROVAL; DRUG INDUSTRY; DRUG POTENTIATION; ENDOCARDITIS; FINANCIAL MANAGEMENT; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMEMBRANOUS COLITIS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; URINARY TRACT INFECTION;

EID: 84865393141     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks213     Document Type: Article

References (62)

1. Thomas Mann website. http://www.thomasmann.de/thomasmann/ home (11 April 2012, date last accessed).
2. Antibiotics-the perfect storm (blog). Pfizer Abandons Antibiotics R&D in China! http://antibiotics-theperfectstorm.blogspot.com/2011/11/pfizerabandons-antibiotics-r-in-china.html (11 April 2012, date last accessed).
3. Bloomberg News. http://www.bloomberg.com/news/2012-03-27/pfizerrises-after-goldman-raises-possibility-of-full-breakup.html (11 April 2012, date last accessed).
4. Wacey D, Kilburn MR, Saunders M et al. Microfossils of sulphur-metabolizing cells in 3.4-billion-year-old rocks of Western Australia. Nature Geoscience 2011; 4: 698-702.
5. Marchant C. Design of clinical trials of antibiotic therapy for acute otitis media. FDA antiinfectives advisory meeting (11 July 2002). www.fda.gov/ ohrms/dockets/ac/02/slides/3875S2_05_Marchant.ppt (22 April 2012, date last accessed).
6. Echols RM, Tillotson GS, File TM Jr. Antibiotic development-déja' vu: Are we facing the pre-antibiotic era again? Infect Dis Clin Practice 2007; 15: 75-8.
7. Julian K, Kosowska-Shick K, Whitener C et al. Characterization of a daptomycin nonsusceptible vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis. Antimicrob Agents Chemother 2007; 51: 3445-8.
8. Appelbaum PC. Reduced glycopeptide susceptibility in methicillinresistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2007; 30: 398-408.
9. Kosowska-Shick K, Clark C, Pankuch GA et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antmicrob Agents Chemother 2009; 53: 4217-24.
10. Saravolatz L, Pawlak J, Johnson J. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycinintermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococus aureus isolates. Antimicrob Agents Chemother 2010; 54: 3027-30.
11. Jones RN, Farrell DJ, Mendes RWet al. Comparative ceftaroline activity tested against pathogens associated with community-associated pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011; 66 Suppl 3: iii69-80.
12. Datamonitor. Product Profiles: Pipeline Antibacterials. Reference Code: HC00130-003 (publication date: January 2012; title pages and index only: complete version has to be purchased). http://www.datamonitor. com/store/Product/toc.aspx?productId=HC00130-003 (11 April 2012, date last accessed).
13. Livermore DM, Mushtaq S, Barker K et al. Characterization of b-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline+avibactam (NXL104). J Antimicrob Chemother 2012; 67: 1354-8.
14. Livermore D, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4.
15. Levasseur P, Girard AM, Claudon M et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL 104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012; 56: 1606-8.
16. Bell JM, Farrell DJ, Jones RN et al. Antimicrobial activity of ceftazidime/ NXL 104 avibactam (CAZ104) tested against Gram-negative organisms causing infections in medical centers from Europe (EU), Latin America (LA) and the Asia-Pacific region (APAC). In: Abstracts of the Fifty-First Interscience Conference on antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract C2-1251. American Society for Microbiology, Washington, DC, USA.
17. Dubreuil L, Mahieux S, Neut C et al. Anti-anaerobic activity of NXL104 in combination with b-lactams and metronidazole. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2009. Abstract E-188. American Society for Microbiology, Washington, DC, USA.
18. Lucast C, Popescu I, Ramesh M et al. Efficacy and safety of ceftazidime/NXL104 plus metronidazole vs. meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults. In: Proceedings of the Twenty-First European Congress of Clinical Microbiology and Infectious Diseases Milan, IT, 2011. Abstract P1532. European Society for Clinical Microbiology and Infection, Paris.
19. Juan C, Zamorano L, Pérez JL et al. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2010; 54: 846-51.
20. Bulik CC, Christensen H, Nicolau DP. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother 2010; 54: 557-9.
21. Sader HS, Rhomberg PR, Farrell DJ et al. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011; 55: 2390-4.
22. Vaara M. Polymixins and their novel derivatives. Curr Opin Microbiol 2010; 13: 574-81.
23. Page MG, Dantier C, Desarbre E. In vitro activities of BAL 30072, a novel siderophore sulfactam with activity against multresistant Gram-negative bacilli. Antimicrob Agents Chemother 2010; 54: 2291-302.
24. Higgins PG, Stefanik D, Page MG et al. In vitro activity of the siderophore monosulfactam BAL 30072 against meropenemnon-susceptible Acinetobacter baumannii. J Antimicrob Chemother 2012; 67: 1167-9.
25. Köhler T, Page MGP, van Delden C. Expression of Fe-uptake systems in Pseudomonas aeruginosa PAO1 and susceptibility to the siderophore sulfactam BAL30072. In: Abstracts of the Fifty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract F1-144. American Society for Microbiology, Washington, DC, USA.
26. Marra A, Bortolon E, Molstad D et al. Completely novel protein synthesis inhibitors demonstrate efficacy in three mouse models of infection. In: Proceedings of the Twenty-First European Congress of Clinical Microbiology and Infectious Diseases Milan, Italy 2011. Abstract 093. http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2011.03557. x/pdf (02 May 2012, date last accessed).
27. DeVito J, Remy J, Bhatacharjee A et al. Antimicrobial activity of a novel programme of protein synthesis inhibitors against clinical isolates containing KPC and NDM-1 carbapenemases. In: Proceedings of the Twenty-First European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy 2011. Abstract P 1162. http://onlinelibrary.wiley. com/doi/10.1111/j.1469-0691.2011.03558.x/pdf (02 May 2012, date last accessed).
28. Kanyo Z, Bhatacharjee A, Chen S et al. Three completely new antibiotic scaffolds for treating multidrug-resistant Gram-negative infections. New targets for new antimicrobials. In: Proceedings of the Twenty-First European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy 2011. Abstract P 1166. http://onlinelibrary.wiley. com/doi/10.1111/j.1469-0691.2011.03558.x/pdf (02 May 2012, date last accessed).
29. Mendes RE, Biedenbach DJ, Alley MRK et al. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against Enterobacteriaceae. In: Abstracts of the Fiftieth Interscience Conference on antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-1638. American Society for Microbiology, Washington, DC, USA.
30. Biedenbach DJ, Mendes RE, Alley MRK et al. Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against non-fermentative Gram-negative bacilli. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract F1-1639. American Society for Microbiology, Washington, DC, USA.
31. Citron DM, Goldstein EJC. Comparative in-vitro activity of GSK2251052, a novel boron leucyl t-RNA inhibitor, against 916 anaerobic organisms. In: Abstracts of the Fifty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011. Abstract E-111. American Society for Microbiology, Washington, DC, USA.
32. Burak E, Bortolon E, Molstad D et al. Pharmacokinetics and pharmacodynamics of delafloxacin in S. aureus mouse thigh infection models. In: Abstracts of the Forty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract A1-1941. American Society for Microbiology, Washington, DC, USA.
33. Bhavnani SM, Lawrence L, Burak E et al. Clinical trial dose selection for delafloxacin for complicated skin and skin structure infection (cSSSI). In: Abstracts of the Forty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract A1-1942. American Society for Microbiology, Washington, DC, USA.
34. Patel M, De Souza NJ, Gupte SV et al. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother 2004; 48: 4754-61.
35. Bhagwat SS, Munkur LA, Gupte SV et al. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother 2006; 50: 3568-79.
36. McKee EE, Ferguson M, Bentley AT et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 2006; 50: 2042-9.
37. Renslo AR. Antibacterial oxazolidinones: emerging structure-toxicity relationships. Expert Rev Anti-Infect Ther 2010; 8: 565-74.
38. Marra A, Bortolon E, Molstad D et al. Evaluation of radezolid against a methicillin-resistant Staphylococcus aureus mouse granuloma pouch infection. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 2010. Abstract A1-015. American Society for Microbiology, Washington, DC, USA.
39. Farrell J, Mendes RE, Sader H et al. Potency of radezolid (Rx-1741) and torezolid (DA-7157) tested against a collection of linezolid-non-susceptible strains with genetically defined resistance mechanisms. In: Proceedings of the Twenty-First European Congress of Clinical Microbiology and Infectious Diseases Milan, IT, 2011. Abstract P1134. http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2011. 03558.x/pdf (02 May 2012, date last accessed).
40. Pichereau S, Bohmuller J, Marchillo K et al. Comparative pharmacodynamics of a novel oxazolidinone, torezolid phosphate (TR-701), against S. aureus in a neutropenic murine pneumonia infection model. In: Abstracts of the Forty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract A1-1939. American Society for Microbiology, Washington, DC, USA.
41. Rodriguez-Avial I, Culebras E, Betriu C et al. In vitro activity of tedizolid (TR 700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012; 67: 167-9.
42. Prokocimer P, Bien P, Surber J et al. Phase 2, randomized, double-blind dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011; 55: 583-92.
43. Török ME, Chapman AL, Lessing MP et al. Outpatient parenteral antimicrobial therapy: recent developments and future prospects. Curr Opin Invest Drugs 2010; 11: 929-39.
44. Grossman TH, Starosta AL, Fyfe C et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 2012; 56: 2559-64.
45. Zhou Y, Yu H, Guo Q et al. Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high resistance to aminoglycosides. Eur J Clin Microbiol Infect Dis 2010; 29: 1349-53.
46. Lin G, Ednie LM, Appelbaum PC. Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob Agents Chemother 2010; 54: 2258-61.
47. Farrell DJ, Castanheira M, Sader HS et al. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). J Infect 2010; 61: 476-83.
48. Bogdanovich T, Bozdogan B, Appelbaum PC. Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. Antimicrob Agents Chemother 2006; 50: 893-8.
49. Critchley IA, Jacobs MR, Brown SD et al. Prevalence of serotype 19A Streptococcus pneumoniae isolates from U.S. children in 2005-2006 and activity of faropenem. Antimicrob Agents Chemother 2008; 52: 2639-43.
50. Witte W, Cuny C. Emergence and spread of cfr-mediated multiresistance in staphylococci: an interdisciplinary challenge. Future Microbiol 2011; 6: 925-31.
51. Fernandes P, Pereira D. Efforts to support the development of fusidic acid in the United States. Clin Infect Dis 2011; 52 Suppl 7: S542-6.
52. Antibiotics-the perfect storm (blog). Telavancin, Astellas and Theravance-Implications? http://antibiotics-theperfectstorm.blogspot. com/2012/01/according-to-recent-press-reports-and.html (11 April 2012, date last accessed).
53. Chisholm SA, Alexander S, Desouza-Thomas L et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother 2011; 66: 2509-12.
54. Infectious Diseases Society of America. Antibiotic development: the 10×20 initiative. http://www.idsociety.org/10x20 (11 April, date last accessed).
55. Cars O, Hedin A, Heddini A. The global need for effective antibiotics- moving towards concerted action. Drug Resistance Updates 2011; 14: 68-9.
56. Alvan G, Edlund C, Heddini A. The global need for effective antibiotics-A summary of plenary presentations. Drug Resistance Updates 2011; 14: 70-6.
57. Wise R. The urgent need for new antibacterial agents. J Antimicrob Chemother 2011; 66: 1939-40.
58. Livermore DM. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011; 66: 1941-4.
59. Finch R. Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. J Antimicrob Chemother 2011; 66: 1945-7.
60. White AR. Effective antibacterials: at what cost? The economics of bacterial resistance. J Antimicrob Chemother 2011; 66: 1948-53.
61. Antibiotic Action homepage. http://antibiotic-action.com (11 April 2012, date last accessed).
62. Innovative Medicines Initiative. Partner search. http://www.europa. eu/content/partner-search (30 May 2012, date last accessed).